Trials / Completed
CompletedNCT02561455
Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial
A Phase 1/2 Open-label Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Astellas Pharma Global Development, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study was to provide access to continued treatment for those who participated in other Astellas sponsored ASP2215 trials that completed the primary analysis and, had the potential to continue to derive clinical benefit from the treatment with ASP2215, and who did not meet any of the study discontinuation criteria in the present study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gilteritinib | oral tablet |
Timeline
- Start date
- 2016-05-03
- Primary completion
- 2020-07-28
- Completion
- 2020-07-28
- First posted
- 2015-09-28
- Last updated
- 2024-11-19
- Results posted
- 2021-08-16
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02561455. Inclusion in this directory is not an endorsement.